Arix Bioscience Limited

Balance Sheet as at 14 September 2016

Balance Sheet

	Note	*As at 14 September 2016 £000*
Non-current assets		
Investments	3	891
Total non-current assets		891
Current assets		
Inter-Company receivables	5	13,012
Cash and cash equivalents		34,490
Total current assets		47,502
Total assets		48,393
Equity and liabilities		
Equity attributable to the owners of the Arix Holdings Group		
Issued share capital	4	51
Retained earnings		48,302
Total equity		48 353
Liabilities		
Current liabilities		
Trade and other payables	6	40
Total current liabilities		40
Total liabilities		40
Total equity and liabilities		48,393

Notes to the financial statements

1 General information

The Directors of Arix Bioscience Limited present the balance sheet for the Company for the period ended 14 September 2016 Arix Bioscience Limited was incorporated on 15 September 2015

The Company has been set up as a holding Company to acquire interests in, and provide strategic and operational oversight to, Group Businesses (either directly or through Arix Holdings Ltd) exclusively in the healthcare and life science sector

Arix Bioscience Limited is incorporated and domiciled in the United Kingdom The address of its registered office is 20 Berkeley Square, London, WIJ 6EQ The registered number is 09777975

2. Accounting Policies

2 1 Basis of preparation

The balance sheet of Arix Bioscience Limited (the "Company") period ended 13 September 2016, have been prepared in accordance with European Union endorsed International Financial Reporting Standards ("IFRS") and those parts of the Companies Act 2006 applicable to companies reporting under IFRS The balance sheet has been prepared for the purposes of re-registering as a plc

2 2 Investment in Subsidiary

An investment in subsidiary is stated in the Company's separate financial statements at cost less impairment losses, if any On disposal of such an investment, the difference between the net disposal proceeds and its carrying amount is included in profit or loss

2.3 Cash and cash equivalents

Cash and cash equivalents comprise cash in hand, short term bank deposits and bank overdrafts to the extent that there is a right to offset against other cash balances For the purposes of the cash flow statement, cash and cash equivalents consist of cash and short term deposits net of outstanding bank overdrafts

2.4 Share capital

Ordinary shares are classified as equity Equity instruments issued by the Company are recorded at the proceeds received, net of direct issue costs

3. Investment in Subsidiary

The following are subsidiaries of the Company

	Ownership %
Arix Bioscience Holdings Limited	100%
Arix Bioscience Inc	100%
Arthurian Life Sciences Limited	100%
Arthurian Life Sciences GP Limited	100%
Arthurian Life Sciences SPV GP Limited	100%

All subsidiaries are incorporated in England and Wales, save for Arix Bioscience Inc, which is incorporated in the United States of America and Arthurian Life Sciences GP Limited which is incorporated in Scotland

Arix Bioscience Holdings Limited and Arix Bioscience Inc are intermediate holding companies Arthurian Life Sciences GP Limited is the general partner of Arthurian Life Sciences SPV Carried Interest Partner LP. Arthurian Life Sciences Limited owns the limited partnership interest in Arthurian Life Sciences SPV Carried Interest Partner LP

4. Share Capital Reorganisation

In order to comply with the statutory requirements to become a plc, the Company transferred £49,670 from the share premium to the issued share capital reserve during September 2016 A further £49,967,040 of share premium was also transferred from the share premium account to the retained earnings account

	As at 14 September 2016
	£000
Allotted and called up	
100,966,920 Ordinary Shares of £0 00001 each	1
28,916,666 Series B Shares of £0 00001 each	-
49,671 Series C Shares of £1 each	50

On incorporation, the Company issued one ordinary share of £1 On 29 September 2015, the Company issued an additional 999 ordinary shares of £1 each at par

On 10 November 2015, each ordinary share of £1 00 each was subdivided into 10,000 Ordinary Shares of £0 00001

On 30 November 2015, the Company issued and allotted 966,920 Ordinary Shares at par

On 8 February 2016, the Company created a new class of Series B Shares of £0 00001 each ("**Series B Shares**") and deferred shares of £0 00001 each (the "**Deferred Shares**") No Deferred Shares have been issued

On 8 February 2016, the Company issued and allotted 27,805,556 Series B Shares at an issue price of £1 80 per share

On 8 February 2016, 97,046,908 of ordinary shares were disenfranchised pursuant to a restrictive share agreement Disenfranchised shares are not entitled to vote, attend meetings of the Company, or to receive dividends or other distributions made or paid on the ordinary shares The restrictive share agreement makes provision of the release of the restrictions in certain circumstances, which includes upon the subscription for future share issues

On 15 April 2016, the Company issued and allotted 1,111,110 Series B Shares at an issue price of £1 80 per share

On 7 June 2016, 156,642 ordinary shares were released from the obligations under the restrictive share agreement.

On 14 September 2016, 49,671 Series C shares were issued and allotted with an issue price of £1 00 per share Series C shares carry no voting nor distribution rights

All other ordinary and Series B shares carry equal voting and distribution rights

A further £49,967,040 also transferred from the share premium account to the retained earnings account as part of the re-registration process

5. Inter-Company receivables

Inter-Company receivables are initially measured at fair value and then subsequently carried at amortised cost using the effective interest method

6 *Trade and other payables*

Trade and other payables are initially measured at fair value and then subsequently carried at amortised cost using the effective interest method